Acorda commences AMPYRA clinical study for post-stoke deficits Acorda Therapeutics.

Post-stoke deficits make reference to chronic neurological deficits, such as for example impaired walking, sensory and motor function and manual dexterity, that persist in individuals who have had a stroke. There are no medications indicated to take care of the currently chronic neurological deficits associated with stroke,’ stated Ron Cohen, M.D., Acorda Therapeutics’ President and CEO. ‘Preclinical data have proven that dalfampridine can improve useful deficits resulting from ischemic stroke, offering a strong basis for this first clinical trial in people who have post-stroke deficits.’ This proof-of-concept research will assess the tolerability and basic safety of AMPYRA in people who have stable post-stroke deficits after an ischemic stroke.Laguna Niguel, CA Windhover's Therapeutic Area Partnerships Conference, 18-20 November, 2013, Boston, MA Affinium was chosen by Windhover among the Top 10 Infectious Disease Tasks to Watch Related StoriesAntibiotic resistance possibly threatens the protection and efficacy of surgical procedures and immunosuppression therapiesVirginia Tech researchers discover new remedies to focus on antibiotic-resistant bacteriaNew study uncovers antibiotic prescription tendencies across England Recent scientific publications consist of: Pharmacokinetics, pharmacodynamics and efficacy of novel FabI inhibitor AFN-1252 against MRSA and MSSA in the murine thigh infection model.